A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management
NCT02078492
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
240
Enrollment
OTHER
Sponsor class
Conditions
Pain
Interventions
DRUG:
10 mg of Ketorolac
DRUG:
15 mg of Ketorolac
DRUG:
30 mg of Ketorolac
Sponsor
Antonios Likourezos